FDA Final Rule on MDI Transition
On April 14, 2010 @ 3:33 pm In All Articles,Medications
[1]The Food and Drug Administration (FDA) has announced that seven more metered dose inhalers (MDIs) containing ozone-depleting propellants will be phased out.
Four of the medications have already been discontinued: Tilade, Intal, Azmacort and Alupent; and two of the remaining three have a small market share: Aerobid and MaxAir. Combivent is used by patients with chronic obstructive pulmonary disease (COPD) and by some patients who have both COPD and asthma.
The phase-out dates for each of these can be read here: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm208302.htm. [2] [^ [2]]
We expect that an Aerobid HFA replacement will be approved prior to its phase-out. We expect the same for Combivent.
Visit our website, http://www.aanma.org [3], for more news and updates from AANMA. Thank you.
Related posts:
Article printed from Allergy and Asthma Network Mothers of Asthmatics: http://www.aanma.org
URL to article: http://www.aanma.org/2010/04/fda-final-rule-on-mdi-transition/
URLs in this post:
[1] Image: http://www.aanma.org/wordpress/wp-content/uploads/FDA_logo.jpg
[2] http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm208302.htm.: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm208302.htm
[3] http://www.aanma.org: http://www.aanma.org
[4] Ask Dr. White: Is This COPD?: http://www.aanma.org/2009/02/ask-dr-white-is-this-copd/
[5] FDA Confirms New Label Language for Medications Containing Long-Acting Beta Agonists (LABAs): http://www.aanma.org/2010/06/fda-confirms-new-label-language-for-medications-containing-long-acting-beta-agonists-labas/
Click here to print.